Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Buhler Industries Inc
Tata Motors Ltd Tata Motors Limited
Westport Fuel Systems Inc - Common Shares
Westport Fuel Systems Inc - Common Shares
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
65.83
-2.46 (-3.60%)
Delayed Quote
Updated: 4:00 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
November 03, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
October 29, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
October 15, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
September 01, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026
From
Exelixis, Inc.
Via
Business Wire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
August 16, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
August 12, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 22, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 30, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
May 27, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 21, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
May 19, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
May 07, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 05, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 21, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
February 10, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
February 02, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
January 27, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
January 11, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 07, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
January 06, 2026
From
Exelixis, Inc.
Via
Business Wire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
December 03, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
November 06, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 04, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
October 20, 2025
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1